

Fluoroquinolone-Based Organic Salts and Ionic Liquids as Highly Bioavailable Broad-Spectrum Antimicrobials [†]

Diogo Madeira ¹, Celso Alves ², Joana Silva ², Catarina Florindo ³, Alexandra Costa ¹, Željko Petrovski ¹, Isabel M. Marrucho ³, Rui Pedrosa ^{2,*}, Miguel M. Santos ^{1,*} and Luís C. Branco ^{1,*}

¹ LAQV-REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal; daa.madeira@campus.fct.unl.pt (D.M.); amp.costa@campus.fct.unl.pt (A.C.); z.petrovski@fct.unl.pt (Ž.P.)

² MARE—Marine and Environmental Sciences Centre, ESTM, Instituto Politécnico de Leiria, 2520-641 Peniche, Portugal; celso.alves@ipleiria.pt (C.A.); joana.m.silva@ipleiria.pt (J.S.)

³ Centro de Química Estrutural, Instituto Superior Técnico, Universidade de Lisboa, Avenida Rovisco Pais, 1049-001 Lisboa, Portugal; catarina_florindo@hotmail.com (C.F.); isabel.marrucho@tecnico.ulisboa.pt (I.M.M.)

* Correspondence: rui.pedrosa@ipleiria.pt (R.P.); miguelmsantos@fct.unl.pt (M.M.S.); l.branco@fct.unl.pt (L.C.B.)

[†] Presented at the 1st International Electronic Conference on Pharmaceutics, 1–15 December 2020; Available online: <https://iecp2020.sciforum.net/>.

Received: date; Accepted: date; Published: date

Abstract: The majority of antibiotics display low oral bioavailability due to reduced solubility in water and/or inefficient permeability across biological membranes. Their efficiency is further limited by the frequent presence of polymorphic structures with different pharmaceutical activities. In this communication we present our latest results on the development of Organic Salts and Ionic Liquids (FQ-OSILs) from fluoroquinolones as highly efficient ionic formulations of this family of antimicrobials. Ciprofloxacin and norfloxacin were used as anions and as cations by combination with biocompatible organic counter-ions. In vitro bioavailability studies showed that all prepared FQ-OSILs present higher solubility in water than the original drugs. All compounds were found to be isomorphic and with tailorable antimicrobial activity according to the cation-anion combination against *S. aureus*, *B. subtilis* and *K. pneumoniae* strains.

Keywords: active pharmaceutical ingredients as organic salts and ionic liquids (API-OSILs); antibiotics; ciprofloxacin; fluoroquinolones; ionic liquids; norfloxacin; polymorphism

1. Introduction

The development of novel antibiotics did not present significant progress over the last years due to low returns, in particular regarding clinical trials. Norfloxacin [1] and ciprofloxacin [2] are the two pioneering antimicrobials from the fluoroquinolone family, which are primarily effective against Gram-negative bacteria. Typically, fluoroquinolones, as many other active pharmaceutical ingredients (APIs), display spontaneous conversion into different polymorphs with different pharmaceutical profiles [4]. Crystal structures of neutral and zwitterionic forms of norfloxacin and ciprofloxacin have been described by Nikaido and Thanassi, with considerable differences in bioavailability [5]. The several different protolytic forms (anionic, neutral, zwitterionic and cationic) presented by these drugs negatively influence their bioavailability in physiological media, which is highly dependent on their low solubility in water [6,7].

For more than a decade, Active Pharmaceutical Ingredients as Organic Salts and Ionic Liquids (API-OSILs) have risen in academia as an alternative formulation for low bioavailable drugs [8]. This third generation of Ionic Liquids consists on the combination of APIs as cations or anions, according to their functional groups, with organic counter-ions. This type of transformation has rendered distinctive physicochemical properties over the original drugs and reduced toxicity to healthy cells, thus enhancing the pharmaceutical activity of the API [9–16]. Our works involving the preparation of API-OSILs from e.g., β -lactam [9–12] and fluoroquinolone [13,14] antibiotics, among others, have shown that the combination of an API, either as a cation or as an anion, with suitable biocompatible counter-ions can increase the water solubility of the parent drug and even change its therapeutic scope. Furthermore, the stability and solubility in physiological media of the API can be significantly altered, yielding novel formulations with different pharmacokinetics and potential different delivery modes and applications [15,16]. In addition, the polymorphic tendency of an API can be considerably reduced, or even eliminated hence tackling one of the most important issues in the pharmaceutical industry which is responsible for limitations in drug's solubility and dosages.

The formation of organic salts based on cationic fluoroquinolones (mostly comprising ciprofloxacin (Cip), but also norfloxacin (Nor)) has been widely explored by the academic community by protonation of drugs' amine group(s). More precisely, these fluoroquinolones have been combined with several dicarboxylic acids [17–21], citric acid [17], as well as with other drugs [22–24] in order to assess bioavailability, crystallinity/amorphous profiles and thermodynamic stability. Some works involve the combination of ciprofloxacin or enrofloxacin as cations and/or as anions, by combination with amino acids [25] and ionic polymers [26,27] have indeed presented for the first time enhanced antimicrobial activity of the salts in comparison with the parent drugs, in particular against Gram-negative bacteria strains.

In this communication we present our works on the synthesis and characterization of novel API-OSILs from Cip and Nor as cations [13] and as anions [14]. In the former, we combined both antimicrobials with methanesulfonate (Mes), gluconate (Glu) and glycolate (Gly) biocompatible anions, while on the latter the combinations were performed with choline (Ch), cetylpyridinium (C₁₆Py) and *N*-methylimidazolium derivatives (xMIM). The synthesized FQ-OSILs were characterized by NMR (¹H and ¹³C) and FTIR spectroscopic techniques, elemental analysis as well as differential scanning calorimetry (DSC). Water solubility at 25 and 37 °C was experimentally determined for the FQ-OSILs, with the exception of the ones containing the [C₁₆Py] cation. Finally, the antimicrobial activity of all FQ-OSILs on Gram-negative (*Klebsiella pneumoniae*) and Gram-positive (*Bacillus subtilis*, *Staphylococcus aureus*) bacteria was determined, and presented here for the first time for the cationic salts.

2. Experiments

2.1. Materials and Methods

2.1.1. General Procedure for the Preparation of Cationic FQ-OSILs

A 1 M solution of the organic acid was added in stoichiometric amounts to a methanolic solution of ciprofloxacin or norfloxacin. After magnetically stirring for 24 h at room temperature, the solvent was evaporated using a rotavapor and the desired FQ-OSIL was obtained in quantitative yield after drying in *vacuo* for 24 h [13].

2.1.2. General Procedure for the Preparation of Anionic FQ-OSILs

The halide salt was dissolved in methanol and passed through an ion-exchange column Amberlite IRA-400-OH (5 eq., flux rate 0.133 mL/mL min). The methanolic solution of the corresponding hydroxide salt was added dropwise to ciprofloxacin or norfloxacin (1.2 eq) completely dissolved in 2 M ammonia solution (50 mL/g). After stirring the mixture for 1 h, the solvent was evaporated in the rotavapor and the crude was recrystallized from a mixture of chloroform

/methanol. Excess fluoroquinolone was filtered off, the solution was evaporated and the desired FQ-OSIL was dried in *vacuo* for 24 h [14].

2.1.3. Determination of the Solubility in Water

An excess amount of compound was added to the corresponding solvent in 1.5 mL vials. Vials were kept under vigorous stirring at 1400 rpm and controlled temperature (25 or 37 °C ± 0.1 °C), using of a *Thermomixer Comfort* (Eppendorf 1.5 mL) and collected at different time periods. The samples were centrifuged in a *Biofuge 28 RS*, *Heraeus Sepatech*, for 10 min at 14000 rpm, in order to enhance physical separation of different phases. The quantification of the liquid phase was accomplished by UV-vis spectroscopy (model UV-1800–Pharma-Spec spectrophotometer from Shimadzu), with quartz cells at a wavelength of 273 (ciprofloxacin) and 275 nm (norfloxacin). Every experiment was conducted in triplicate, and a calibration curve was previously established for each compound (for all curves $R^2 > 0.998$).

2.1.4. Cytotoxicity of Compounds

Cytotoxic activities of FQ-OSILs were studied on 3T3 cells previously acquired from DSMZ biobank. Cells were cultured in Dulbecco's Modified Eagle's medium: Nutrient Mix F-12 (DMEM/F-12) (Merck, Germany) supplemented with 10% FBS (Gibco, Grand Island, NY, USA), GlutaMAX™ (Gibco, Grand Island, NY, USA), 100 IU/mL penicillin, and 100 µg/mL streptomycin (Sigma, St. Louis, MO, USA). For subculture, 3T3 cells were dissociated using trypsin-EDTA (Sigma, USA), splitted 1:5 ratio, and seeded into Petri dishes with 25 cm² of growth area. Culture medium was replaced every 2 days until cells reached the total confluence after 3-5 days of initial seeding. Cells were maintained in humidified atmosphere (95%), 5% CO₂ and 37 °C. Cytotoxicity was evaluated on 3T3 cells' viability after cells reached total confluence. Cells were treated with samples at 10 µM for 24 h. Samples effects were assessed by using MTT (Sigma, Germany), and the results were expressed in percentage of control (%).

2.1.5. Antimicrobial Activities

Antimicrobial activity of FQ-OSILs was evaluated against *Bacillus subtilis* (ATCC 6633) and *Staphylococcus aureus* (ATCC 25,923) grown in Lysogeny broth (LB) and *Klebsiella pneumoniae* (ATCC 11,296) grown in Tryptic soy broth. All mediums were obtained from Merck (Darmstadt, Germany). The antimicrobial activity was accompanied by optical density at 600 nm in order to verify the ability of compounds to inhibit the microorganisms growth (Synergy H1 Multi-Mode Microplate Reader, BioTek® Instruments, Vermont, USA). The IC₅₀ was determined (0.001–10 nM) for the most potent samples (microorganism growth inhibition >50% at 10 µM). Results were expressed in percentage of growth inhibition relative to the control (growth medium with microorganism).

2.1.6. Statistical Analysis

Statistical analysis was performed using one-way analysis of variance (ANOVA) with Dunnett's multiple comparison of group means to determine significant differences relatively to control treatment. Results are presented as mean ± standard error of the mean (SEM). Differences were considered statistically significant at a level of 0.05 (p -value < 0.05). The determination of IC₅₀ was performed by the analysis of non-linear regression by means of the equation:


$$y = \frac{100}{[1+10^{(x-\log(IC_{50}))}]}$$

Calculations were performed using GraphPad v5.1 (GraphPad Software, La Jolla, CA, USA) software.

3. Results and Discussion

3.1. Synthesis

Ciprofloxacin and norfloxacin were combined as anions and as cations with biocompatible counter-ions by following well-established methodologies. In the case of the cationic FQ-OSILs, methanolic solutions of the organic acids (mesylic, gluconic and glycolic) were added to a solution of the fluoroquinolones, yielding the corresponding FQ-OSILs in quantitative yields (Scheme 1A). As for the anionic FQ-OSILs, we followed a in-house developed methodology for the preparation of API-OSILs from zwitterionic drugs [12,15]. More precisely, we dissolved the drugs in ammonia buffered solution in order to prepare the corresponding ammonium salts *in situ*, which were subsequently exchanged with choline [Ch], 1-ethyl-3-methylimidazolium [EMIM], 1-hydroxy-ethyl-3-methylimidazolium [C₂OHMIM], 1-(2-hydroxyethyl)-2,3-dimethylimidazolium [C₂OHDMIM], 1-(2-methoxyethyl)-3-methylimidazolium [C₃OMIM] and cetylpyridinium [C₁₆Py] cations as hydroxide bases. These were freshly prepared from the corresponding halide cations by anion exchange using Amberlyst IRA-400 (OH⁻) resin (Scheme 1B). The desired FQ-OSILs were obtained in 93–100% yields upon recrystallization.



Scheme 1. Synthetic methodology for the preparation of (A) cationic and (B) anionic FQ-OSILs.

3.2. Spectroscopic Characterization

All products were characterized by ¹H and ¹³C NMR and FTIR spectroscopic techniques, as well as elemental analysis.

In all cases the ¹H NMR spectra showed that the cation/anion proportion is strictly 1.0:1.0, in agreement with the intended stoichiometry. In addition, only one set of signals was observed, meaning that the reactions were complete and only one product was formed.

Regarding the FTIR spectra of the cationic compounds, there are no clear signals consistent with the deprotonation of the organic acids due to superimposition with the drugs' amine signals at 1630 cm⁻¹. However, a signal at 1721 cm⁻¹ is consistent with the presence of the fluoroquinolone's carboxylic acid group, which is absent in the FTIR spectra of the parent drugs. This observation is only achievable if the drugs' structure is no longer zwitterionic, and hence, it's is protonated at the secondary nitrogen atom. In the case of the anionic FQ-OSILs, there are only slight changes in some vibration frequencies, in particular from the free Cip and Nor carboxylate group (respectively 1589 and 1583 cm⁻¹) to 1581–1575 and 1583–1579 cm⁻¹ in the final respective salts. In all cases, the 3600–3300 cm⁻¹ area displays strong signals in the spectra of the final compounds, as opposed to the initial ones, which suggests the establishment of H-bonds between the cations and the anions.

3.3. Thermal Analysis

All prepared FQ-OSILs were studied by Differential Scanning Calorimetry (DSC). Table 1 contains the obtained data, namely melting and glass transition temperatures, as well as the physical state at room temperature of the analysed compounds.

Table 1. Physical state at room temperature, melting (T_m) and glass transition (T_g) temperatures ciprofloxacin, norfloxacin and corresponding OSILs.

Compound	Physical State	$T_m/^\circ\text{C}$	$T_g/^\circ\text{C}$
Cip	White solid	322.0	-
[Cip][Mes]	Pale yellow solid	145.5	125.2
[Cip][Glu]	Pale yellow solid	146 dec.	122.9
[Cip][Gly]	White solid	153.7	-
[Ch][Cip]	Pale yellow solid	111.2	-
[EMIM][Cip]	White solid	92.9	36.7
[C ₂ OHMIM][Cip]	White solid	111.6	49.5
[C ₂ OHDMMIM][Cip]	White solid	197.5	-
[C ₃ OMIM][Cip]	White solid	112.4	46.4
[C ₁₆ Py][Cip]	Orange viscous liquid	-	-10.7
Nor	White solid	217.0	
[Nor][Mes]	Pale yellow solid	168.2	-
[Nor][Glu]	Yellow viscous liquid	-	1.8
[Nor][Gly]	White solid	115.3	91.6
[Ch][Nor]	Pale yellow solid	94.5	54.8
[EMIM][Nor]	Yellow solid	119.9	64.6
[C ₂ OHMIM][Nor]	Yellow viscous liquid	-	41.1
[C ₂ OHDMMIM][Nor]	White solid	121.8	65.1
[C ₃ OMIM][Nor]	White viscous liquid	-	44.1
[C ₁₆ Py][Nor]	Yellow viscous liquid	-	5.9

All prepared salts display lower melting temperatures than the parent fluoroquinolones, as expected. In general, ciprofloxacin-based OSILs have a higher tendency to become solid at room temperature than norfloxacin ones. In fact, from the former, only [C₁₆Py][Cip] was found to be a Room Temperature Ionic Liquid (RTIL), while with the latter five were obtained as solids and four as RTILs. All solid FQ-OSILs presented as non-polymorphic at the studied conditions.

3.4. Water Solubility Studies

All FQ-OSILs present higher solubility in water at 25 and 37 °C than the parent FQs (Figure 1).




Figure 1. Water solubility at 25 °C (green) and 37 °C (yellow) for ciprofloxacin, norfloxacin and corresponding OSILs. The dotted line represents the upper experimental threshold.

The general tendency points to less soluble anionic FQ-OSILs in comparison with the cationic analogues. The most soluble salts based on both fluoroquinolones present the gluconate anion, which is consistent with the highly hydrophilic character of this carbohydrate. In fact, [Nor][Glu] is entirely soluble in water at both temperatures. As for the anionic FQ-OSILs, the observed general tendency is in agreement with the hydrophilic character of the studied cations.

3.5. Antimicrobial Activity Studies

The antimicrobial activity (IC₅₀) of the prepared FQ-OSILs and the corresponding starting materials was determined against Gram-negative (*Klebsiella pneumoniae*) and Gram-positive (*Staphylococcus aureus*, *Bacillus subtilis*) bacteria strains (Table 2).

Table 2. IC₅₀ values (nM) for ciprofloxacin and corresponding OSILs (0.001–10 μM) against the tested microorganisms. The values in parentheses represent the confidence intervals for 95%.

Compounds	<i>K. pneumoniae</i>	RDIC ₅₀	<i>S. aureus</i>	RDIC ₅₀	<i>B. subtilis</i>	RDIC ₅₀
Cip	196.50	-	29.16	-	3.84	-
[Cip][Mes]	55.07	3.6	31.96	0.91	14.38	0.3
[Cip][Glu]	74.52	2.6	29.81	1.0	12.16	0.3
[Cip][Gly]	82.79	2.4	24.06	1.2	19.78	0.2
[Ch][Cip]	51.12	3.8	181.40	0.2	20.60	0.2
[EMIM][Cip]	64.80	3.0	24.24	1.2	16.17	0.2
[C ₂ OHMIM][Cip]	36.42	5.4	61.95	0.5	15.75	0.2
[C ₂ OHDMIM][Cip]	50.99	3.9	21.20	1.4	12.35	0.3
[C ₃ OMIM][Cip]	47.61	4.1	82.05	0.4	21.66	0.2
[C ₁₆ Py][Cip]	9.88	19.9	1430	0.0	6.07	0.6
Nor	255.2	-	123.4	-	117.2	-
[Nor][Mes]	203.8	1.3	230.3	0.5	65.12	1.8
[Nor][Glu]	225.2	1.1	176	0.7	98.67	1.2
[Nor][Gly]	242.4	1.1	118.2	1.0	67.49	1.7
[Ch][Nor]	199.4	1.3	127.1	1.0	95.49	1.2
[EMIM][Nor]	207.5	1.2	211.2	0.6	24.48	4.8
[C ₂ OHMIM][Nor]	201.0	1.3	91.70	1.3	88.61	1.3
[C ₂ OHDMIM][Nor]	178.2	1.4	79.55	1.6	148.8	0.8
[C ₃ OMIM][Nor]	224.5	1.1	106.7	1.1	68.12	1.7
[C ₁₆ Py][Nor]	202.9	1.3	10.84	11.4	87.29	1.3

In general, both anionic and cationic Cip-based OSILs were found to be more active against the pathogenic strains than the Nor analogues. The former were particularly active against *K. pneumoniae*, with Relative Decreases of IC₅₀ (RDIC₅₀) between 2.4 ([Cip][Gly]) and 19.9 ([C₁₆Py][Cip]). [EMIM][Cip] and [C₂OHDMIM][Cip] also recorded 40% increased activity against *S. aureus*. Moreover, a decreased activity against commensal *B. subtilis* was also desirably observable. The most promising Nor-based OSILs were [C₂OHDMIM][Nor], with a 40–60% increase in activity against the pathogenic strains, and [C₁₆Py][Nor], with selective 11.4-fold increased activity against *S. aureus*.

4. Conclusions

In this work we were able to show two simple and straightforward methods for the preparation of cationic and anionic non-polymorphic FQ-OSILs, which present very high water solubilities and tailorable antimicrobial activities against sensitive pathogenic and commensal bacteria strains according to the established cation-anion combinations. These results may pave the way for the

future development of personalized ionic formulations of antimicrobials with selective or broad-spectrum activities, according to patient need.

Author Contributions: Conceptualization, L.C.B. and Ž.P.; methodology and investigation, M.M.S., C.A., J.S., D.M., C.F., A.C.; validation, M.M.S., I.M.M., R.P. and L.C.B.; writing—Original draft preparation, M.M.S., C.A. and C.F.; writing—review and editing, M.M.S., C.A., I.M.M. and L.C.B.; supervision, I.M.M., R.P. and L.C.B.; funding acquisition, I.M.M., R.P. and L.C.B. All authors have read and agreed to the published version of the manuscript.

Acknowledgments: This work was supported by the Associate Laboratory for Green Chemistry LAQV and Centro de Química Estrutural which are financed by national funds from FCT/MCTES (UIDB/50006/2020 and UID/QUI/00100/2013, respectively). The authors also thank Fundação para a Ciência e Tecnologia for the projects PTDC/QUI-QOR/32406/2017, PEst-C/LA0006/2013 and RECI/BBBBQB/0230/2012, as well as one contract under Investigador FCT (L. C. Branco).

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

API	Active Pharmaceutical Ingredient
API-OSILs	Active Pharmaceutical Ingredient Organic Salts and Ionic Liquids
C ₁₆ Py	cetylpyridinium
C ₂ OHDMMIM	1-(2-hydroxyethyl)-2,3-dimethylimidazolium
C ₂ OHMIM	1-(2-hydroxyethyl)-3-methylimidazolium
C ₃ OMIM	1-(2-methoxyethyl)-3-methylimidazolium
Ch	choline
Cip	ciprofloxacin
EMIM	1-ethyl-3-methylimidazolium
FQ	fluoroquinolone
FQ-OSILs	fluoroquinolone-based organic salts and ionic liquids
IC ₅₀	half maximal inhibitory concentration
Nor	norfloxacin
OSIL	Organic Salt and Ionic Liquid
RDIC ₅₀	Relative Decrease in Inhibitory Concentration for 50% bacterial growth
RTILs	Room Temperature Ionic Liquids
T _g	glass transition temperature
T _m	melting temperature

References

1. Holmes, B.; Brogden, R.N.; Richards, D.M. Norfloxacin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. *Drugs* **1985**, *30*, 482–513.
2. Sharma, P.C.; Jain, A.; Jain, S.; Pahwa, R.; Yar, M.S. Ciprofloxacin: Review on developments in synthetic, analytical, and medicinal aspects. *J. Enz. Inhib. Med. Chem.* **2010**, *25*, 577–589.
3. Emmerson, A.M.; Jones, A.M. The quinolones: Decades of development and use. *J. Antimicrob. Chemother.* **2003**, *51*, 13–20.
4. Variankaval, N.; Cote, A.S.; Doherty, M.F. From form to function: Crystallization of active pharmaceutical ingredients. *AIChE J.* **2008**, *54*, 1682–1688.
5. Nikaido, H.; Thanassi, D.G. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: Tetracyclines and fluoroquinolones as examples. *Antimicrob. Agents Chemother.* **1993**, *37*, 1393–1399.
6. Yu, X.; Zipp, G.; Davidson, G.W.R., III. The effect of temperature and pH on the solubility of quinolone compounds: Estimation of heat of fusion. *Pharm. Res.* **1994**, *11*, 522–527.
7. Varanda, F.; Pratas de Melo, M.J.; Caço, A.I.; Dohrn, R.; Makrydaki, F.A.; Voutsas, E.; Tassios, D.; Marrucho, I.M. Solubility of antibiotics in different solvents. 1. Hydrochloride forms of tetracycline, moxifloxacin, and ciprofloxacin. *Ind. Eng. Chem. Res.* **2006**, *45*, 6368–6374.
8. Egorova, K.S.; Gordeev, E.G.; Ananikov, V.P. Biological Activity of Ionic Liquids and Their Application in Pharmaceuticals and Medicine. *Chem. Rev.* **2017**, *117*, 7132–7189.
9. Ferraz, R.; Branco, L.C.; Marrucho, I.; Araújo, J.; da Ponte, M.N.; Prudêncio, C.; Noronha, J.P.; Petrovski, Z.; Development of Novel Ionic Liquids-APIs based on Ampicillin derivatives. *Med. Chem. Comm.* **2012**, *3*, 494–497.

10. Florindo, C.; Araujo, J.M.M.; Alves, F.; Matos, C.; Ferraz, R.; Prudencio, C.; Noronha, J.P.; Petrovski, Z.; Branco, L.; Rebelo, L.P.N.; et al. Evaluation of solubility and partition properties of ampicillin-based ionic liquids. *Int. J. Pharm.* **2013**, *456*, 553–559.
11. Ferraz, R.; Teixeira, V.; Rodrigues, D.; Fernandes, R.; Prudencio, C.; Noronha, J.P.; Petrovski, Z.; Branco, L.C. Antibacterial activity of Ionic Liquids based on ampicillin against resistant bacteria. *RSC Adv.* **2014**, *4*, 4301–4307.
12. Ferraz, R.; Silva, D.; Dias, A.R.; Dias, V.; Santos, M.M.; Pinheiro, L.; Prudencio, C.; Noronha, J.P.; Petrovski, Z.; Branco, L.C. Synthesis and Antibacterial Activity of Ionic Liquids and Organic Salts based on Penicillin G and Amoxicillin hydrolysate derivatives against Resistant Bacteria. *Pharmaceutics* **2020**, *12*, 221.
13. Florindo, C.; Costa, A.; Matos, C.; Nunes, S.L.; Matias, A.N.; Duarte, C.M.M.; Rebelo, L.P.N.; Branco, L.C.; Marrucho, I.M. Novel organic salts based on fluoroquinolone drugs: Synthesis, bioavailability and toxicological profiles. *Int. J. Pharm.* **2014**, *469*, 179–189.
14. Santos, M.M.; Alves, C.; Silva, J.; Florindo, C.; Costa, A.; Petrovski, Ž.; Marrucho, I.M.; Pedrosa, R.; Branco, L.C. Antimicrobial Activities of Highly Bioavailable Organic Salts and Ionic Liquids from Fluoroquinolones. *Pharmaceutics* **2020**, *12*, 694.
15. Wu, H.; Deng, Z.; Zhou, B.; Qi, M.; Hong, M.; Ren, G. Improved transdermal permeability of ibuprofen by ionic liquid technology: Correlation between counterion structure and the physicochemical and biological properties. *J. Mol. Liq.* **2019**, *283*, 399–409.
16. Sidat, Z.; Marimuthu, T.; Kumar, P.; du Toit, L.C.; Kondiah, P.P.D.; Choonara, Y.E.; Pillay, V. Ionic Liquids as Potential and Synergistic Permeation Enhancers for Transdermal Drug Delivery. *Pharmaceutics* **2019**, *11*, 96.
17. Reddy, J.S.; Ganesh, S.V.; Nagalapalli, R.; Dandela, R.; Solomon, K.A.; Kumar, K.A.; Goud, N.R.; Nangia, A. Fluoroquinolone salts with carboxylic acids. *J. Pharm. Sci.* **2011**, *100*, 3160–3176.
18. Surov, A.O.; Voronin, A.P.; Drozd, K.V.; Churakov, A.V.; Roussel, P.; Perlovich, G.L. Diversity of crystal structures and physicochemical properties of ciprofloxacin and norfloxacin salts with fumaric acid. *CrystEngComm* **2018**, *20*, 755–767.
19. Surov, A.O.; Manin, A.N.; Voronin, A.P.; Drozd, K.V.; Simagina, A.A.; Churakov, A.V.; Perlovich, G.L. Pharmaceutical salts of ciprofloxacin with dicarboxylic acids. *Eur. J. Pharm. Sci.* **2015**, *77*, 112–121.
20. Surov, A.O.; Churakov, A.V.; Perlovich, G.L. Three Polymorphic Forms of Ciprofloxacin Maleate: Formation Pathways, Crystal Structures, Calculations, and Thermodynamic Stability Aspects. *Cryst. Growth Des.* **2016**, *16*, 6556–6567.
21. Paluch, K.J.; McCabe, T.; Müller-Bunz, H.; Corrigan, O.I.; Healy, A.M.; Tajber, L. Formation and physicochemical properties of crystalline and amorphous salts with different stoichiometries formed between ciprofloxacin and succinic acid. *Mol. Pharmaceutics*. **2013**, *10*, 3640–3654.
22. Bag, P.P.; Ghosh, S.; Khan, H.; Devarapalli, R.; Reddy, C.M. Drug–drug salt forms of ciprofloxacin with diflunisal and indoprofen. *CrystEngComm* **2014**, *16*, 7393–7396.
23. Surov, A.O.; Vasilev, N.A.; Churakov, A.V.; Stroh, J.; Emmerling, F.; Perlovich, G.L. Solid Forms of Ciprofloxacin Salicylate: Polymorphism, Formation Pathways, and Thermodynamic Stability. *Cryst. Growth Des.* **2019**, *19*, 2979–2990.
24. Golovnev, N.N.; Molokeev, M.S.; Lesnikov, M.K.; Atuchin, V.V. Two salts and the salt cocrystal of ciprofloxacin with thiobarbituric and barbituric acids: The structure and properties. *J. Phys. Org. Chem.* **2018**, *31*, 1–11.
25. Mesallati, H.; Conroy, D.; Hudson, S.; Tajber, L. Preparation and Characterization of Amorphous Ciprofloxacin-Amino Acid Salts. *Eur. J. Pharm. Biopharm.* **2017**, *121*, 73–89.
26. Mesallati, H.; Umerska, A.; Paluch, K.J.; Tajber, L. Amorphous Polymeric Drug Salts as Ionic Solid Dispersion Forms of Ciprofloxacin. *Mol. Pharm.* **2017**, *14*, 2209–2223.
27. Mesallati, H.; Umerska, A.; Tajber, L. Fluoroquinolone Amorphous Polymeric Salts and Dispersions for Veterinary Uses. *Pharmaceutics* **2019**, *11*, 268.

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© 2020 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).